Rekah Pharmaceutical Industry Stock Earnings Per Share
| REKA Stock | ILA 1,279 46.00 3.47% |
Rekah Pharmaceutical Industry fundamentals help investors to digest information that contributes to Rekah Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Rekah Stock. The fundamental analysis module provides a way to measure Rekah Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rekah Pharmaceutical stock.
Rekah |
Rekah Pharmaceutical Industry Company Earnings Per Share Analysis
Rekah Pharmaceutical's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Rekah Pharmaceutical Earnings Per Share | 0.32 X |
Most of Rekah Pharmaceutical's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rekah Pharmaceutical Industry is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Rekah Pharmaceutical Industry has an Earnings Per Share of 0.32 times. This is 96.18% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The earnings per share for all Israel stocks is 89.74% higher than that of the company.
Rekah Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rekah Pharmaceutical's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rekah Pharmaceutical could also be used in its relative valuation, which is a method of valuing Rekah Pharmaceutical by comparing valuation metrics of similar companies.Rekah Pharmaceutical is currently under evaluation in earnings per share category among related companies.
Rekah Fundamentals
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 316.92 M | |||
| Shares Outstanding | 11.41 M | |||
| Shares Owned By Insiders | 37.27 % | |||
| Shares Owned By Institutions | 42.66 % | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 263.95 M | |||
| Gross Profit | 65.16 M | |||
| EBITDA | 36.2 M | |||
| Net Income | 6.62 M | |||
| Cash And Equivalents | 31.61 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 101.23 M | |||
| Debt To Equity | 1.01 % | |||
| Current Ratio | 1.99 X | |||
| Book Value Per Share | 14.39 X | |||
| Cash Flow From Operations | 21.17 M | |||
| Earnings Per Share | 0.32 X | |||
| Number Of Employees | 399 | |||
| Beta | 0.0605 | |||
| Market Capitalization | 193.93 M | |||
| Total Asset | 437.09 M | |||
| Retained Earnings | 49 M | |||
| Working Capital | 156 M | |||
| Current Asset | 246 M | |||
| Current Liabilities | 90 M | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 437.09 M | |||
| Last Dividend Paid | 0.87 |
About Rekah Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rekah Pharmaceutical Industry's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rekah Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rekah Pharmaceutical Industry based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rekah Pharmaceutical Industry. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |